Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Jazz Pharmaceuticals Appoints Executive Vice President and Chief Financial Officer | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Jazz Pharmaceuticals Appoints Executive Vice President and Chief Financial Officer

Philip Johnson joins Jazz with over 35 years of financial experience.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Jazz Pharmaceuticals plc, which recently agreed to acquire Redx’s KRAS (Kirsten rat sarcoma virus) inhibitor program, has appointed Philip Johnson as Executive Vice President and Chief Financial Officer, effective March 1, 2024.
 
Johnson succeeds Renée Galá, who was promoted to President and Chief Operating Officer in October 2023.

Experience

Johnson joins Jazz Pharmaceuticals with over 35 years of financial experience, most recently leading Eli Lilly and Company’s treasury and investor relations operations as Group Vice President of Finance.
 
In his new role, he will oversee financial reporting, accounting, tax, treasury, risk management, financial planning and analysis, information services and facilities. He will also oversee the company’s investor relations and corporate development functions.
 
“Jazz is a highly respected company with a strong financial foundation and significant opportunities for growth and value creation. It is exciting to join an innovative and science-driven organization deeply committed to addressing the unmet needs of patients who may have limited treatment options,” said Johnson. “I am thrilled to bring my cross-functional expertise to my new role and build upon the team’s momentum to continue to grow and diversify Jazz’s global business.”
 
“Phil’s deep financial acumen, strategic mindset and proven leadership abilities are an ideal fit for Jazz. Phil’s appointment follows a comprehensive search process to identify the right financial leader as we continue to execute against our strategy to grow and diversify our global business,” remarked Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals. “I am thrilled to welcome Phil to Jazz and look forward to working closely with him to deliver enhanced shareholder value.”

Other Jazz News

Autifony Therapeutics recently entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters